Delivery Order SPE2DB24D2109-SPE2DB25FHXAB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,013.24 to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count packaging) on June 9, 2025, with a completion date of June 10, 2025. This firm fixed-price, non-set-aside delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $12,785.44 to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract is classified as a delivery order and will be performed at the contractor's location in Conshohocken, Pennsylvania. Sprycel is a targeted cancer therapy medication, reflecting the Defense Logistics Agency's ongoing...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $18,543.22 to AmerisourceBergen Drug Corp for the supply of Sprycel 70 mg tablets (60-count units). This competitive award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count units) under a firm fixed-price contract valued at $35,010.98. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed without set-aside designation. Performance of this pharmaceutical supply contract will be fulfilled from AmerisourceBergen's Corporate Office location...
- The Defense Logistics Agency awarded a delivery order valued at $5,578.09 to AmerisourceBergen Drug Corp for Sprycel 50 mg tablets (60-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,964.90 to AmerisourceBergen Drug Corp for Sprycel 100 mg tablets (30-count units) on July 17, 2025, with completion scheduled for July 18, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Sprycel 140 mg tablets (30-count units) under a firm fixed-price contract. The delivery order, valued at $5,570.37 with a completion date of July 29, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $11,156.18 to AmerisourceBergen Drug Corp for Sprycel 50 mg tablets (quantity: 60 units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order valued at $10,387.97 to AmerisourceBergen Drug Corp for Sprycel 100 mg tablets (30-count) on May 5, 2025, with completion expected by May 6, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical supply transaction under the company's existing contract vehicle with DLA. The award carries no set-aside designation and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania...
- The Defense Logistics Agency awarded a $16,591.33 delivery order to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count units) under a firm fixed-price contract. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against AmerisourceBergen's existing pharmaceutical supply contract vehicle. Performance will be executed from the company's corporate office location in Conshohocken,...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB25FHXABDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,667.58 to AmerisourceBergen Drug Corp for the supply of Sprycel 50 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order was issued on May 19, 2025, with an ultimate completion date of May 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Sprycel is a targeted cancer therapy medication, and this delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) SPE2DX with DLA Troop Support Medical, a $999.9 billion prime vendor agreement running through December 2026 that supports pharmaceutical and medical supply distribution globally for military healthcare systems. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems through this comprehensive contract vehicle. The company's extensive federal portfolio demonstrates its capability to deliver a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains to support military personnel and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 5/19/25 |